Advertisement
Advertisement
PTCT
PTC Therapeutics, Inc.
63.30
USDSponsored
+1.02
+1.65%
Sep 25, 13:07 UTC -4
Open
PTCT Earnings Reports
Positive Surprise Ratio
PTCT beat 16 of 43 last estimates.
37%
Next Report
Date of Next Report
Oct 22, 2026
Estimate for Q3 26 (Revenue/ EPS)
$309.98M
/$0.45
Implied change from Q2 26 (Revenue/ EPS)
-14.02%
/-51.09%
Implied change from Q3 25 (Revenue/ EPS)
+46.90%
/+125.00%
PTC Therapeutics, Inc. earnings per share and revenue
On Jul 30, 2026, PTCT reported earnings of 0.92 USD per share (EPS) for Q2 26, beating the estimate of 0.42 USD, resulting in a 116.37% surprise. Revenue reached 360.52 million, compared to an expected 304.94 million, with a 18.23% difference. The market reacted with a -9.94% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of 0.45 USD, with revenue projected to reach 309.98 million USD, implying an decrease of -51.09% EPS, and decrease of -14.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were PTC Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, PTC Therapeutics, Inc. reported EPS of $0.92, beating estimates by 116.37%, and revenue of $360.52M, 18.23% above expectations.
How did the market react to PTC Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved down -9.94%, changed from $75.52 before the earnings release to $68.01 the day after.
When is PTC Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Oct 22, 2026.
What are the forecasts for PTC Therapeutics, Inc.'s next earnings report?
Based on 10
analysts, PTC Therapeutics, Inc. is expected to report EPS of $0.45 and revenue of $309.98M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.